Non-cystic fibrosis (non-CF) bronchiectasis is a pathological condition characterized by inflamed, dilated, and thick-walled bronchi. Conditions predisposing to bronchiectasis include host immune defects, post-infective sequelae, and defects in mucociliary clearance ([@bib27]), although in most cases no cause can be found. Bronchiectasis is notable for chronic sputum production, recurrent lower respiratory tract infections, and persistent bacterial colonization. Such patients frequently undergo a vicious cycle of events: failure to clear bacterial infections followed by inflammatory responses that further impair host defenses and mucociliary clearance, resulting in chronic inflammation that in turn leads to persistent bacterial colonization ([@bib36]). *Pseudomonas aeruginosa* is isolated in up to 30% of adult patients with bronchiectasis ([@bib28]) and is a risk factor for declining lung function ([@bib23]); it is also associated with reduced quality of life and a poorer prognosis ([@bib37]; [@bib22]; [@bib1]). Once established, it is difficult to eradicate and is often resistant to numerous antibiotics, making routine management less effective. Therefore, understanding both the infecting bacterium and the response to the infection is vital to combat this disease.

Examination of the literature reveals a single report of a patient with bronchiectasis with impaired serum-killing of *P. aeruginosa* who died despite treatment ([@bib34]). We hypothesized that similar impaired serum-killing also exists for other bronchiectasis patients with chronic *Pseudomonas* infections and that this contributes to disease severity. Indeed, IgG antibody to *P. aeruginosa* and complement components are readily detectable in the serum and sputum of patients with bronchiectasis ([@bib15]), and these factors are known to opsonize colonizing *P. aeruginosa* in the lung ([@bib14]; [@bib15]). Thus, it is highly likely that antibody-mediated killing is involved in the host defense against bacterial lung infection. Here, we sought to establish if impaired serum killing is a common phenomenon in patients with bronchiectasis and to elucidate the mechanism underpinning a lack of serum bactericidal activity. In addition, we sought to identify if the lack of serum bactericidal activity in patients had a correlation with disease severity.

RESULTS
=======

Impaired serum killing in bronchiectasis patients
-------------------------------------------------

Historical data associated impaired serum-killing of *P. aeruginosa* with poor outcome in a patient with bronchiectasis ([@bib34]). To explore if this is an isolated event or a more general phenomenon, we examined the serum sensitivity of *P. aeruginosa* isolates taken from 11 different patients with bronchiectasis and chronic *Pseudomonas* infection ([Table 1](#tbl1){ref-type="table"}). Serum was collected from each patient and 20 healthy individuals. Each patient (P) and their isolated bacterium (B) and serum (S) were assigned the same number; patient P1, with serum S1, is colonized by *P. aeruginosa* B1. We found that eight patients had serum (S4--11) that could kill their cognate colonizing strain (B4-11), but three patients had serum (S1--3) that failed to kill their infecting strains (B1--3; [Fig. 1 A](#fig1){ref-type="fig"}). The bactericidal activity of the eight sera (S4--11) was inactivated by heat treatment, implying that serum killing was caused by the action of complement (unpublished data). The strains from patients with impaired bacterial killing were not innately resistant to killing, as sera from 20 healthy human controls (HCS) and sera from patients with bronchiectasis but without *P. aeruginosa* colonization (SN18--30) killed these three strains within 45 min ([Fig. 1 B](#fig1){ref-type="fig"}). Similar results were found for B2 and B3 (unpublished data).

###### 

Disease severity of bronchiectasis patients, with or without IgG2 blocking factor

  Patient ID                                          Colonized with *P. aeruginosa?*   Serum ID   Does serum mixed with HCS kill B1   FEV1% predicted
  --------------------------------------------------- --------------------------------- ---------- ----------------------------------- -------------------------------------
  Impaired serum killing, *P. aeruginosa* colonized                                                                                    
  P1                                                  Yes- B1                           S1         No                                  28
  P2                                                  Yes- B2                           S2         No                                  66
  P3                                                  Yes- B3                           S3         No                                  26
  PN1                                                 Yes- BN1                          SN1        No                                  17
  PN2                                                 Yes- BN2                          SN2        No                                  37
  PN3                                                 Yes- BN3                          SN3        No                                  31
  Normal killing, *P. aeruginosa* colonized                                                                                            
  P4                                                  Yes- B4                           S4         Yes                                 105
  P5                                                  Yes- B5                           S5         Yes                                 78
  P6                                                  Yes- B6                           S6         Yes                                 97
  P7                                                  Yes- B7                           S7         Yes                                 43
  P8                                                  Yes- B8                           S8         Yes                                 59
  P9                                                  Yes- B9                           S9         Yes                                 64
  P10                                                 Yes- B10                          S10        Yes                                 90
  P11                                                 Yes- B11                          S11        Yes                                 68
  PN4                                                 Yes- BN4                          SN4        Yes                                 61
  PN5                                                 Yes- BN5                          SN5        Yes                                 52
  PN6                                                 Yes- BN6                          SN6        Yes                                 67
  PN7                                                 Yes- BN7                          SN7        Yes                                 85
  PN8                                                 Yes- BN8                          SN8        Yes                                 42
  PN9                                                 Yes- BN9                          SN9        Yes                                 93
  PN10                                                Yes- BN10                         SN10       Yes                                 65
  PN11                                                Yes- BN11                         SN11       Yes                                 54
  PN12                                                Yes- BN12                         SN12       Yes                                 43
  PN13                                                Yes- BN13                         SN13       Yes                                 48
  PN14                                                Yes- BN14                         SN14       Yes                                 75
  PN15                                                Yes- BN15                         SN15       Yes                                 101
  PN16                                                Yes- BN16                         SN16       Yes                                 58
  PN17                                                Yes- BN17                         SN17       Yes                                 32
  Normal killing, Not colonized by *P. aeruginosa*                                                                                     
  PN18                                                No                                SN18       Yes                                 46
  PN19                                                No                                SN19       Yes                                 70
  PN20                                                No                                SN20       Yes                                 35
  PN21                                                No                                SN21       Yes                                 46
  PN22                                                No                                SN22       Yes                                 52
  PN23                                                No                                SN23       Yes                                 78
  PN24                                                No                                SN24       Yes                                 22
  PN25                                                No                                SN25       Yes                                 54
  PN26                                                No                                SN26       Yes                                 63
  PN27                                                No                                SN27       Yes                                 69
  PN28                                                No                                SN28       Yes                                 62
  PN29                                                No                                SN29       Yes                                 23
  PN30                                                No                                SN30       Yes                                 58
  Patients with cystic fibrosis and *P. aeruginosa*                                                                                    
  CF1                                                 Yes                               SCF1       Yes                                 ND[a](#tblfn1){ref-type="table-fn"}
  CF2                                                 Yes                               SCF2       No                                  ND
  CF3                                                 Yes                               SCF3       Yes                                 ND
  CF4                                                 Yes                               SCF4       Yes                                 ND
  CF5                                                 Yes                               SCF5       Yes                                 ND
  CF6                                                 Yes                               SCF6       No                                  ND
  CF7                                                 Yes                               SCF7       Yes                                 ND
  CF8                                                 Yes                               SCF8       Yes                                 ND

Not determined.

![**Identification of patients with impaired serum killing.** (A) Killing curves of *P. aeruginosa* strains isolated from bronchiectasis patients with their autologous serum at 45, 90, and 180 min. Negative values correspond with a decrease in viable *P. aeruginosa* compared with initial concentration. (B) Killing of B1 by sera taken from 20 healthy people at 45, 90, and 180 min. Killing of B1 by sera from patients with bronchiectasis but without *P. aeruginosa* colonization (SN18--SN30) is also shown. The curves depicting killing by HCS1-HCS20 and SN18-SN30 are overlaid to simplify. (C) Killing curves of all strains (B1--B11) by serum (S1). (D) Killing curves of *P. aeruginosa* strain B1 by patient serum (S1--S11). (E) Killing curves of B1 and B4 by sera SN1, 2, and 3 (SN1--3). (F) Killing curves of B1 and B4 by sera SN4--SN17. The curves depicting killing by SN4--SN17 are overlaid to simplify graphs. For all serum bactericidal assays, error bars represent the mean ± SD for a minimum of three independent experiments.](JEM_20132444_Fig1){#fig1}

Next, we tested each patient's serum against all 11 of the *P. aeruginosa* isolates. We found that S1--3 could not kill B1--3 but could kill the *P. aeruginosa* strains from the other 8 patients ([Fig. 1 C](#fig1){ref-type="fig"}). In contrast, S4--11 could kill B1--3 ([Fig. 1 D](#fig1){ref-type="fig"}). This suggests the factors mediating resistance to serum killing are common to B1--3 and S1--3 but absent from the other strains and sera. We extended this analysis by testing sera (SN1--17) isolated from patients with bronchiectasis from a geographically distinct cohort who were colonized with *P. aeruginosa* ([Table 1](#tbl1){ref-type="table"}). Three sera (SN1--3) failed to kill strain B1 but could kill strain B4, whereas the remainder (SN4--17) could affect serum-mediated killing of both B1 and B4 ([Table 1](#tbl1){ref-type="table"} and [Fig. 1, E and F](#fig1){ref-type="fig"}). A similar phenomenon was observed for a small sample of patients with cystic fibrosis ([Table 1](#tbl1){ref-type="table"}). Thus, ∼20% of the patients with bronchiectasis and *P. aeruginosa* infection had impaired serum killing of their strains, and the factor involved appeared to be specific both to the patient sera and the infecting *P. aeruginosa* strain.

Impaired serum contains a blocking factor
-----------------------------------------

We next explored whether the impaired serum killing results from an inhibitory factor present within the serum or from the lack of a serum component required for bactericidal activity. Specific anti--*P. aeruginosa* IgG, IgA, and IgM were present in the sera with impaired capacity to kill, at levels comparable to or greater than those in HCS that killed all the bacterial isolates ([Fig. 2 A](#fig2){ref-type="fig"}). Furthermore, IgG and complement components C1q, C3, and the C5b-9 membrane attack complex (MAC) were deposited on all strains ([Fig. 2, A and B](#fig2){ref-type="fig"}). Antibody binding and complement deposition were confirmed by immunofluorescence microscopy (unpublished data). Thus, the impaired serum killing is not due to a lack of complement or antibody binding.

![**Impaired serum is caused by a blocking factor, not a lack of antibody or complement.** (A) Binding of specific IgG, IgM, IgA antibodies and C1q and C3 complement factors from indicated patient serum to B1, B2, and B3. Each strain was tested with autologous serum and at least three separate healthy controls. Data are representative of three independent experiments. (B) Serum titers of *P. aeruginosa*--specific IgG compared with C5b-9 MAC deposition on autologous strains. (C) Inhibition of HCS-mediated killing of strains B1--3 with a 50:50 mix of HCS and autologous patient sera (S1--3). Dashed lines represent HCS mixed 50:50 with buffer. (D) Killing of *P. aeruginosa* strains B1--3 at 180 min by mixed sera consisting of different percentages of HCS mixed with autologous serum. For all data, error bars represent the mean ± SD for a minimum of three independent experiments.](JEM_20132444_Fig2){#fig2}

To determine if the lack of bacterial killing was due to a blocking factor in the serum, we mixed serum with impaired killing with HCS. Addition of HCS to S1--3 (50:50) did not restore serum killing, whereas HCS similarly diluted with PBS readily killed *P. aeruginosa* ([Fig. 2 C](#fig2){ref-type="fig"}). These data suggest that impaired serum-killing by S1--3 is caused by the presence of a factor inhibiting serum-mediated killing. In fact, complete killing by S1--3 was only restored when HCS represented 94, 70, and 80%, respectively, of the mixed sera ([Fig. 2 D](#fig2){ref-type="fig"}), indicating the patients serum had a potent capacity to inhibit killing.

IgG blocks the ability for serum to kill specific *Pseudomonas* strains
-----------------------------------------------------------------------

We established that the impaired serum killing of patients' cognate *Pseudomonas* strains is due to a blocking factor in their serum. To identify the inhibitor, S1 was fractionated, based on molecular weight, and fractions were added to HCS. Inhibition was observed when the 100--300-kD fraction was added to HCS ([Fig. 3 A](#fig3){ref-type="fig"}). As this fraction contains IgG antibody, we investigated whether depleting antibody could restore bactericidal activity. Antibody was depleted by passing S1 over either a Protein A or a Protein G column, reducing total IgG titers ∼100-fold ([Fig. 3 B](#fig3){ref-type="fig"}). We found that the inhibitory serum S1, when depleted of antibody using either a Protein A or G column, could kill B1 within 180 min. Moreover, when mixed with HCS (50:50), B1 was rapidly killed indicating that the antibody-depleted serum no longer had the capacity to inhibit the bactericidal activity of HCS ([Fig. 3 C](#fig3){ref-type="fig"}). Importantly, antibodies eluted from the Protein A and G columns, in a volume equal to that of S1 originally applied to the column, inhibited the bactericidal activity of HCS, even when added at low concentrations (4--6%; [Fig. 3 D](#fig3){ref-type="fig"}). Similar observations were made for S2 and S3 (unpublished data). Due to the different antibody binding affinities of Protein A and G ([Table S1](http://www.jem.org/cgi/content/full/jem.20132444/DC1Fig){#supp1}), these findings suggest IgG is the blocking factor present in S1--3.

![**IgG inhibits serum-mediated killing.** (A) Killing of B1 by HCS mixed 50:50 with S1 and HCS fractionated into indicated size ranges. The killing curves for several fractions overlap and have been separated to allow for visualization. Data are representative of three independent experiments. (B) Titer of total IgG1 and IgG2 of S1 serum before and after passing through Protein A and G columns. Data are representative of two independent experiments. (C) Killing curves of *P. aeruginosa* strain B1 by serum S1. Killing was measured for S1 depleted of antibody using a Protein G column, before and after addition of HCS (50:50). Data are representative of three independent experiments. (D) IgG purified from S1 using a Protein G column was resuspended in PBS to the same volume of serum loaded on the column. Purified IgG was added to HCS in indicated concentrations and measured for its ability to kill B1 at 45, 90, and 180 min. Data are representative of three independent experiments. Error bars represent the mean ± SD.](JEM_20132444_Fig3){#fig3}

IgG2 is the inhibitory factor in impaired serum
-----------------------------------------------

All of the initial cohort of 11 patients had normal proportions of the four IgG subclasses overall ([Table 2](#tbl2){ref-type="table"}); however, to determine if a specific IgG isotype could be responsible for the impaired killing of bacteria by serum seen in 3 patients, the titer of each IgG sub-class specific for *P. aeruginosa* was determined. Anti--*P. aeruginosa* IgG1 titers were not statistically different between impaired and normal killing sera groups ([Fig. 4 A](#fig4){ref-type="fig"}), and neither were levels of IgG3 and IgG4 (not depicted). In contrast, S1--3 had significantly (P \< 0.001) increased titers of anti--*P. aeruginosa* IgG2 compared with sera displaying normal bactericidal activity ([Fig. 4 A](#fig4){ref-type="fig"}). To test if IgG2 is the inhibitory factor, we purified IgG2 from S1 by passing the serum over an affinity column coated with a monoclonal antibody against human IgG2 ([@bib17]). The IgG2-depleted flow-through lost its inhibitory capacity. In contradistinction, IgG2 eluted from the column, in the same volume of serum loaded on the column, blocked the serum bactericidal activity of HCS ([Fig. 4 B](#fig4){ref-type="fig"}).

###### 

Total antibody titers of bronchiectasis patients

  Patient        IgG          IgA                                      IgM
  -------------- ------------ ---------------------------------------- ------------
  P1             10.73        2.2                                      1.07
  P2             12.66        2.17                                     0.82
  P3             10.69        4.49                                     1.05
  P4             11.81        4.06                                     1.29
  P5             11.18        1.51                                     4.19
  P6             11.91        3.4                                      1.64
  P7             16.64        10.37[a](#tblfn2){ref-type="table-fn"}   0.73
  P8             15.6         3                                        3.08
  P9             14.5         3.59                                     1.15
  P10            13.89        2.78                                     0.99
  P11            12.5         1.87                                     0.77
  Normal range   6.0--16.00   0.8--4.0                                 0.50--2.00

No paraprotein detected by IMFIX.

![**IgG2 inhibits serum-mediated killing.** (A) Titers of IgG1 and IgG2 isotypes in patient serum and HCS that is specific to infecting strains. Dashed line indicates the median IgG2 titer from sera S4--S11. Data are representative of three independent experiments. \*\*\*, P \< 0.001. (B) Killing of B1 was measured with S1 depleted of IgG2 mixed with HCS or with a mixture HCS supplemented with IgG2 purified from S1 or HCS alone. For all data, error bars represent the mean ± SD for a minimum of three independent experiments.](JEM_20132444_Fig4){#fig4}

LPS is the target of the inhibitory IgG2
----------------------------------------

To determine if the inhibitory IgG2 antibody targeted a specific bacterial factor, we performed Western immunoblotting of outer membrane protein and polysaccharide fractions with patient serum and anti--human IgG. S1 contained antibodies that recognized proteins from all strains ([Fig. 5 A](#fig5){ref-type="fig"}). In contrast, the serum only recognized the O-antigen side chains of LPS from B1--3 and did not recognize O-antigen of strains from patients without impaired serum killing ([Fig. 5 B](#fig5){ref-type="fig"}). Similar results were obtained for S2 and S3, whereas HCS had no detectable anti--O-antigen antibody to B1--3 ([Fig. 5 C](#fig5){ref-type="fig"}). SDS-PAGE and silver staining of LPS fractions revealed that the strains B1, B2, and B3 produced significant amounts of long-chain O-antigen but the other strains did not ([Fig. 5 D](#fig5){ref-type="fig"}).

![**Inhibitory antibody recognizes *P. aeruginosa* LPS and is dose dependent.** (A) Western blot of outer membrane protein fractions obtained from B1--B11 probed with S1 as a primary antibody and anti--human IgG as the secondary antibody. (B) Polysaccharide-only preparations from *P. aeruginosa* isolates analyzed by Western blot probed with S1 serum as a primary antibody and anti-IgG as a secondary antibody. (C) Western blot of LPS purified from B1, B2, and B3 probed with S2, S3, or HCS as the primary antibody and anti--human IgG as the secondary antibody. S2 and S3 have high LPS-specific IgG response. In contrast, no anti-LPS IgG is detected in HCS. All Western blots (A--C) are representative of three independent experiments. (D) Polysaccharide-only preparations from *P. aeruginosa* isolates are analyzed by silver stain. Data are representative of six independent experiments. (E) Patient serum IgG titer specific for LPS isolated from B1 determined by ELISA. LPS was isolated from *P. aeruginosa* strain B1 and attached to a 96-well plate. ELISA was performed with dilutions of patient or healthy sera and anti--human IgG conjugated to alkaline phosphatase. Error bars represent mean ± SD for three independent experiments. (F) Antibodies specific for B1 LPS were purified and concentrated from S4. S1 and anti-LPS antibodies concentrated from S4 were used as primary antibodies in a Western blot against B1 LPS. Data represents three independent experiments. (G) Killing curve of B1 with anti-LPS antibodies concentrated from S4 mixed with HCS. HCS serum similarly diluted with buffer is used as a control. Error bars represent mean ± SD for three independent experiments.](JEM_20132444_Fig5){#fig5}

By binding the LPS isolated from B1 to an ELISA plate we determined that the patients with impaired serum-mediated bacterial killing had high levels of anti-LPS IgG by ELISA ([Fig. 5 E](#fig5){ref-type="fig"}). To test if the level of anti-LPS antibody is responsible for this effect, rather than simply the presence of anti-LPS antibodies per se, we purified anti-LPS antibodies from S4, a serum that has normal bactericidal activity. The eluted antibodies, concentrated 10-fold on the column ([Fig. 5 F](#fig5){ref-type="fig"}), inhibited the bactericidal activity of HCS in a dose-dependent manner ([Fig. 5 G](#fig5){ref-type="fig"}), indicating the titer of anti-LPS antibody in serum is critical for inhibition.

Antibodies against O-antigen, but not lipid A or core, inhibit serum killing
----------------------------------------------------------------------------

The three strains that could not be killed by serum containing blocking IgG2 possessed high amounts of O-antigen. These observations suggest the long-chain O-antigen of LPS is the target of inhibitory antibody. To test this, LPS purified from B1 was immobilized on a polymyxin-B agarose column and S1 was passed through the column to remove antibody specific to the LPS ([Fig. 6 A](#fig6){ref-type="fig"}). The recovered flow-through fraction was now able to kill B1 and no longer inhibited the killing activity of HCS ([Fig. 6 B](#fig6){ref-type="fig"}). Conversely, anti-LPS antibody eluted from the column inhibited the bactericidal activity of HCS in a dose-dependent manner ([Fig. 6, A and C](#fig6){ref-type="fig"}). Immunofluorescence microscopy revealed that the flow-through fraction lacked detectable anti--*P. aeruginosa* IgG2 (unpublished data). In contrast, anti--*P. aeruginosa* IgG1 remained detectable in the serum depleted of anti-LPS antibody ([Fig. 6 A](#fig6){ref-type="fig"}).

![**Inhibitory antibodies are specific for the O-antigen.** (A) Schematic of treatment of S1 serum and resultant IgG titers specific to LPS purified from either B1 (with O-antigen) or B4 (without O-antigen). S1 titers against the two LPS extracts are measured after no treatment, passage through, or elution from a column containing purified B1 LPS or passage through or elution from a column containing B4 LPS. In each case, all column fractions were resuspended in PBS to the same volume of serum added to the column. (B) Killing curve of *P. aeruginosa* B1 treated with S1 or S1:HCS (50:50) depleted of anti-LPS antibodies. (C) Killing curve of B1 after incubation with anti-LPS antibodies purified from S1 and mixed with HCS at different concentrations. (D) Killing curve of *P. aeruginosa* B1 treated with HCS mixed with either S1 depleted of antibodies to the lipid A and core oligosaccharides of LPS or antibodies that recognize lipid A and core oligosaccharide. For all data, error bars represent the mean ± SD of three independent experiments.](JEM_20132444_Fig6){#fig6}

All *P. aeruginosa* strains contain lipid A and core oligosaccharide of LPS. Consequently, we depleted S1 of antibody to lipid A and the core elements by passing S1 over a polymyxin B column on which LPS isolated from B4, which lacks O-antigen, was immobilized ([Fig. 6 A](#fig6){ref-type="fig"}). The flow-through antibody had a 30-fold lower level of binding to lipid A and core oligosaccharide compared with both the native serum and the antibody eluted from the column ([Fig. 6 A](#fig6){ref-type="fig"}). However, the flow through from this column still recognized O-antigen--containing LPS purified from B1 at a level similar to native S1 ([Fig. 6 A](#fig6){ref-type="fig"}). This flow-through inhibited the killing of B1 by HCS, but the antibody recognizing lipid A and core oligosaccharide eluted from the column did not ([Fig. 6 D](#fig6){ref-type="fig"}). These data are summarized in Fig. S1.

The role of inhibitory antibodies in the lung
---------------------------------------------

The role of serum-mediated killing in controlling bacterial growth during lung infection is not widely recognized. However, previously high levels of antibody were shown to be present in the lungs of patients suffering from bronchiectasis ([@bib15]). We hypothesized that patients with impaired immunity and *P. aeruginosa* colonization would have high titers of IgG2 present in the lung. To confirm this, the sol phase of sputum from P2 (impaired killing) and P4 (normal killing) was harvested and the levels of IgG1 and IgG2 were measured. P2 sol phase sputum had 512 and 220 mg/liter IgG1 and IgG2, respectively, whereas P4 sol phase contained 315 mg/liter IgG1 and 158 mg/liter IgG2.

Having demonstrated the presence of antibody in the lung, we next sought to determine whether this antibody played a role in protecting bacteria from serum-mediated killing in vivo. To establish this, we first investigated whether *P. aeruginosa* was opsonized by antibody in vivo. Immunofluorescence microscopy of sputum smears revealed bacteria present within the sputum were labeled with anti--human IgG2-FITC ([Fig. 7 A](#fig7){ref-type="fig"}). Additional investigations revealed cultured bacteria could also be labeled with IgG2 when opsonized with 1:200 sol phase sputum ([Fig. 7 A](#fig7){ref-type="fig"}). To confirm that this opsonization protects bacteria from complement-dependent killing, we explored whether HCS could kill bacteria from sputum. The unfiltered sol phase of sputum from P2, containing opsonized bacteria, was mixed 50:50 with HCS; however, there was no reduction in bacterial numbers over 180 min of incubation ([Fig. 7 B](#fig7){ref-type="fig"}). To confirm this phenomenon, B1 was incubated with a mixture of HCS and sterile sol-phase from P2. No complement-dependent killing was observed over 180 min. In contrast, B1 incubated with a mixture of HCS and sterile sol-phase from P4 was rapidly killed within 45 min ([Fig. 7 B](#fig7){ref-type="fig"}).

![**Significance of inhibitory antibodies in vivo.** (A) Immunofluorescence labeling of bacteria present in sputum with anti--human IgG2-FITC (top left). Immunofluorescence labeling of cultured B1 bacteria with sol-phase sputum (top middle) or patient serum (top right) used as the source of primary antibody and anti--human IgG2-FITC. Bottom images are corresponding light images. Bar, 2 µm. (B) Killing curves for bacteria already present in P2 sputum after mixing the unfiltered sol phase with HCS 50:50. Killing curves for B1 with a 40:60 mix of HCS and sterile sol phase sputum isolated from either P2 or P4 are also shown. Error bars represent the mean ± SD of three independent experiments. (C) Killing curves for B1 or B4 by washed peripheral blood cells after 20-min opsonization with a 1/10 dilution of HCS, S1, or S4. Negative values correspond with a decrease in viable *P. aeruginosa* compared with initial concentration. Error bars represent the mean ± SD of three independent experiments. (D) Biofilm formation of B1 after overnight growth followed by no treatment or exposure to HCS, S1, or S4 serum for 2 h. Biofilm formation was examined in polystyrene microtiter plates. Error bars represent the mean ± SD of 16 independent experiments. \*\*, P \< 0.01.](JEM_20132444_Fig7){#fig7}

Opsonization is important for cell-mediated killing, which is known to play a vital protective role within the lung ([@bib36]). We hypothesized that inhibitory antibodies may also play a role in cell-mediated killing. Thus, we investigated killing of B1 and B4 by washed peripheral blood cells. B1 opsonized with HCS was rapidly killed on incubation with peripheral blood cells. Similarly, opsonization of B4 with either HCS or S1 led to rapid killing of the bacteria. In contrast, B1 opsonized with S1 was not killed ([Fig. 7 C](#fig7){ref-type="fig"}).

These data suggest an important role for inhibitory antibody in protecting bacteria within the lung from immune-mediated clearance. However, it is accepted that *P. aeruginosa* resides in a biofilm within the lung. Therefore, we investigated the effect of serum on an established biofilm. B1 forms a thick biofilm in a 96-well plate over 24 h. Incubation of the B1 biofilm with HCS and S4 sera for 2 h drastically reduced the amount of biofilm. In contrast, S1 had no effect on the amount of biofilm over a similar period ([Fig. 7 D](#fig7){ref-type="fig"}).

Patients with inhibitory antibodies have worse lung function
------------------------------------------------------------

The results of the aforementioned in vivo and in vitro studies suggest that the presence of inhibitory antibody may have clinical relevance. Thus, we sought to determine whether patients with bronchiectasis and inhibitory levels of anti-LPS IgG2 antibody had more marked disease severity than those patients whose serum could mediate killing. We used forced expiratory volume in 1 s (FEV1) as a measure of lung function. Individuals colonized with *P. aeruginosa* who also possessed inhibitory antibody had poorer lung function when compared with individuals colonized with *P. aeruginosa* whose serum displayed normal killing (P \< 0.002) and patients with bronchiectasis who were not colonized with *P. aeruginosa* (P \< 0.05; [Fig. 8 A](#fig8){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). This indicates the impaired capacity to kill bacteria has clinical consequences. Interestingly, a similar proportion of patients from two different cohorts displayed IgG2-mediated inhibition of serum killing, suggesting there may be an underlying genetic, rather than acquired, basis for an elevated response ([Table 1](#tbl1){ref-type="table"}).

![**Inhibitory IgG2 antibody is associated with poor lung function.** (A) Comparison of FEV1% predicted values for patients from two non-CF bronchiectasis cohorts that are colonized with *P. aeruginosa* and display inhibition of serum mediated killing (●), patients who are colonized with *P. aeruginosa* and display normal serum-mediated killing (○), or patients who are not colonized with *P. aeruginosa* (□). The horizontal bars represent the median for each group. FEV1% scores represent mean of three independent measurements. \*, P \< 0.05; \*\*, P \< 0.01.](JEM_20132444_Fig8){#fig8}

DISCUSSION
==========

Antibody is usually associated with protection against infectious disease. In contrast, antibody-dependent enhancement of infection is seen for some microbial organisms, most notably viruses such as dengue fever ([@bib12]), but to a lesser extent parasitic organisms such as leishmaniasis ([@bib13]). In the case of dengue fever, circulating antibodies bind to the newly infecting virus but do not neutralize infection. Instead, these antibodies enhance viral entry via efficient interaction of the virus--antibody complex with Fc receptors ([@bib13]; [@bib9]). However, the action of antibody in exacerbating bacterial infectious disease is less well understood. Our results indicate that in patients with bronchiectasis, who are chronically colonized with *P. aeruginosa*, the presence of high titers of IgG2 antibodies specific for the O-antigen of LPS impairs serum-mediated killing of the infecting strain and is associated with a poorer lung function. Here, we describe antibody-dependent enhancement of bacterial infection and demonstrate the mechanism is different to that for dengue.

Lack of serum bactericidal activity against *P. aeruginosa* has previously been noted for patients with CF ([@bib34]; [@bib11]). Moreover, increased anti-LPS antibody titers have been noted in CF patients chronically infected with *P. aeruginosa* ([@bib8]). Separately, high levels of IgG3 and IgG2 specific for lipid A and O-antigen were shown to correlate with deteriorating pulmonary function ([@bib18]). In contrast, our data demonstrate that in bronchiectasis patients, high titers of IgG2 specific for the O-antigen of LPS are sufficient to impair serum-mediated killing of *P. aeruginosa*. Importantly, high titers of IgG2 in the sputum are associated with phenotypes within the lung, including opsonization of infecting bacteria, inhibition of cell-mediated killing, and lack of biofilm clearance.

The biological properties of IgG2 may be a factor in its role as an inhibitor of serum- and/or cell-mediated killing. Switching to IgG2 is particularly associated with responses to bacterial polysaccharides ([@bib32]) but, in contrast to IgG1 and IgG3, the C1q-binding sites on IgG2 are frequently not exposed on antigen binding ([@bib4]; [@bib31]). IgG2 also binds to only one class of FcγR (FcγRII), whereas other IgG classes bind multiple classes ([@bib25]; [@bib31]). Indeed, IgG2 antibodies have been seen to exert antiphagocytic effects on *P. aeruginosa* ([@bib16]). However, we hypothesize that anti--O-antigen IgG2 inhibits killing of the *P. aeruginosa* strains by a mechanism similar to that recently described for nontyphoidal *Salmonella enterica* infection in some HIV-infected Malawian adults ([@bib21]). Thus, inhibitory IgG2 antibodies bind O-antigen, a target distal on the LPS molecule, and exert their inhibitory effect either by activating and depositing complement away from the bacterial membrane and preventing MAC insertion or by blocking access of protective antibody ([@bib2]; [@bib24]; [@bib21]). However, we have yet to establish whether low titers of anti--O-antigen IgG2 can promote bacterial killing without the addition of other protective antibodies ([@bib33]). Notably, in the *Salmonella* study, although IgG was found to be inhibitory in the serum, the specific isotype conferring inhibition was not identified. Furthermore, in the current study, the impaired serum killing is not associated with HIV infection or an immunocompromised state.

Our findings have significant implications for vaccine design. Currently, LPS is thought to be an optimal target for protective antibodies. Three O-antigen--based vaccines against *P. aeruginosa*, Pseudogen, PEV-01, and Aerugen, have reached phase II or III trials ([@bib29]; [@bib19]; [@bib6]). However, two vaccines resulted in worse clinical status in the vaccinated group and the third trial was suspended ([@bib5]; [@bib7]). These studies have not detailed the IgG subclasses induced in response to the vaccine. The current study provides a potential mechanistic basis for the failure of these vaccines strategies. It indicates that candidate O-antigen polysaccharide-based vaccines may elicit imbalanced anti--O-antigen (IgG2 dominant) antibody induction, rendering the vaccine ineffective while increasing the susceptibility to life-threatening *P. aeruginosa* infections. Furthermore, historical reports of the association of impaired serum killing with other bacterial infections suggest this mechanism may be common for a wide variety of Gram-negative bacterial infections ([@bib34]). Importantly, understanding the impact elevated levels of IgG2 have on infections could provide opportunities to attenuate disease in several clinical settings.

MATERIALS AND METHODS
=====================

### Patient details, strains, and samples.

Bronchiectasis patients with and without chronic *P. aeruginosa* colonization were identified and confirmed by CT scan. Eleven bronchiectasis patients with chronic *P. aeruginosa* colonization were identified. *P. aeruginosa* was isolated by sputum culture on chocolate blood agar and *Pseudomonas* isolation agar and subsequently cultured in Luria broth. Serum was collected from each patient and 20 healthy individuals. Each patient (P), their isolated bacterium (B), and serum (S) were assigned the same number; patient P1, with serum S1, is colonized by *P. aeruginosa* B1 ([Table 1](#tbl1){ref-type="table"}). In the absence of a widely recognized disease severity index in bronchiectasis, the degree of lung function impairment was evaluated using forced expiratory volume in 1 s (FEV1) as a percent predicted of a normal FEV1. This work was performed in compliance with the human ethical approval guidelines granted by the Birmingham Ethics Committee (code RRK3404) and Newcastle and North Tyneside Research Ethics committee (code 12/NE/0248). Additional serum samples were obtained from patients with bronchiectasis regardless of whether they had *P. aeruginosa* colonization or not. These samples were from a distinct geographical location (Newcastle) and each patient (PN), their isolated *P. aeruginosa* if present (BN), and serum (SN) were assigned the same number. Serum samples from eight patients with cystic fibrosis (SCF) and *Pseudomonas* colonization were from Birmingham. Colonization was defined by positive *P. aeruginosa* culture from sputum on at least two separate occasions.

### Analysis and manipulation of serum.

Serum bactericidal assays were performed in triplicate using a modification of the method described [@bib21]. In brief, bacteria were grown overnight in 5 ml of LB at 37°C and resuspended in PBS to a final concentration of 10^7^ CFU/ml; 10 µl was then mixed with 90 µl of undiluted human serum at 37°C with shaking (180 rpm), and viable counts were determined. Serum mixing experiments were performed by first mixing the serum with either PBS, concentrated antibodies, other sera, unfiltered sol phase of sputum or sterile sol phase of sputum at the ratios described in text in a final volume of 90 µl before addition of bacteria. Killing was confirmed as caused by the activity of complement by 56°C heat inactivating the serum as a control. Killing of *Pseudomonas* by washed peripheral blood cells was performed as previously described ([@bib10]). In brief, bacteria were grown and resuspended in PBS as above before 10 µl was added to 90 µl of 1/10 dilution of sera (or PBS) for 20-min opsonization. At this point 10 µl this suspension was added to 90 µl of blood cells washed twice in RPMI. Samples were incubated on a rocker plate at 20 rpm at 37°C and numbers of viable *Pseudomonas* were determined after 45, 90, and 180 min by serial dilution on Luria Bertani agar.

Complement deposition and antibody binding were quantified essentially as previously described ([@bib21]). In brief, 5 µl *Pseudomonas* at an OD~600~ = 0.6 was mixed with 45 µl 10% serum (antibody determination) or undiluted serum (complement deposition) for 1 h at room temperature. After 3 washes with PBS a final incubation with FITC-conjugated anti--human immunoglobulin (Total IgG, IgG1, IgG2, IgG3, IgG4, IgA, IgM; Sigma-Aldrich) and anti-C1, C3, and C5b-9 (Dako). The C5b-9 antibody recognizes a neo-epitope on the MAC that only forms when the MAC assembles. After this final incubation, the cells were washed as before and analyzed on a FACSAria II (BD). Total IgG subtype concentrations in sol phase sputum and serum samples were determined using the Human IgG Subclass Single Dilution Bindarid kit (Binding Site).

Fixation and preparation of *Pseudomonas* and sputum for cell imaging was performed as described previously ([@bib20]). In brief, poly L-lysine--coated coverslips loaded with fixed cells or a sputum streak were washed three times with PBS, and nonspecific binding sites were blocked for 1 h in PBS containing 1% BSA (Europa Bioproducts). Coverslips were incubated with 1:500 diluted serum or sol-phase sputum for 1 h, washed three times with PBS, and incubated for an additional 1 h with FITC-conjugated anti--human immunoglobulin (total IgG, IgG1, IgG2, IgG3, IgG4, IgA, IgM; Sigma-Aldrich). The coverslips were then washed three times with PBS, mounted onto glass slides, and visualized using either phase contrast or fluorescence using Leica DMRE fluorescence microscope (100× objective)-DC200 digital camera system.

Serum was fractionated with ultrafiltration columns (Vivascience) with 300, 100, and 30-kD size exclusion filters. In brief, 1 ml of serum was passed first through the 300-kD column as per manufacturer's instructions. Both the flow-through fraction and the retained fraction were diluted to a final concentration of 1 ml with PBS. The 1 ml flow-through fraction was then passed through the 100-kD column in the same way before the final passage through the 30-kD column. All four fractions (\>300, 300--100, 100--30, and \<30 kD) were brought to 1 ml final volume with PBS.

Antibodies were removed from serum using Protein A--Sepharose 4B, Protein G-Sepharose (GE Healthcare) or anti--human IgG2 monoclonal HP6200-Sepharose according to the manufacturer's instructions. All fractions retained were buffer exchanged into PBS to the desired volume before use in assays. Anti-LPS antibodies were removed from serum in the following manner. First, the LPS fraction was purified and quantified from the *Pseudomonas* using the method described below. The LPS preparation was diluted to 1 mg/ml and 1 ml mixed in microcentrifuge tube with 1 ml polymyxin-B agarose (Sigma-Aldrich) overnight at 4°C. The polymyxin B agarose has a binding capacity of 500 µg/ml so should be saturated with *Pseudomonas* LPS. The resin mix was then loaded onto the column and washed with 10 ml of 0.1 M ammonium bicarbonate buffer (pH 8.0). The serum was then passed over the column and washed with an additional 10 ml of buffer. Finally, bound antibody was eluted with a pH gradient of citric acid before buffer exchange into PBS.

*P. aeruginosa* biofilm formation was grown as described previously ([@bib35]). In brief, 150 µl low-density *P. aeruginosa* culture was incubated in a 96-well plate overnight at 37°C shaking. Nonadherent culture was then removed and replaced with 150 µl of serum or LB and incubated at 37°C for 2 h. Supernatant was then removed and the biofilm stained with crystal violet. Biofilm intensity was measured at 595 nm.

### Analysis of bacterial fractions.

Bacterial cell fractions were isolated and analyzed as previously described ([@bib3]; [@bib26]). In brief, outer membrane proteins were isolated by first separating the cell envelopes from the cytoplasm, after French pressure lysis of bacterial cells, by centrifugation (48,000 *g* for 60 min at 4°C). The envelopes were retained and were resuspended in 3 ml of buffer (2% \[vol/vol\] Triton X-100, 10 mM Tris-HCl, pH 7.5) and incubated at 25°C for 15 min to solubilize inner membrane components. Triton X-100--extracted envelopes were harvested by centrifugation at 48,000 *g* for 60 min at 4°C and washed four times in 30 ml of 10 mM Tris-HCl, pH 7.5. Insoluble fractions were resuspended in 1 ml 10 mM Tris-HCl pH 7.5 and stored at −20°C.

LPS was isolated as previously described ([@bib3]). In brief, *Pseudomonas* was grown overnight at 37°C. The equivalent of 1 ml of OD~600~ = 1 culture was spun and the pellet resuspended in 100 µl of lysing buffer (1 M Tris, pH 6.8, 2% SDS, and 4% 2-mercaptoethanol). The suspension was then boiled for 10 min, spun down, and supernatant was moved to a fresh Eppendorf. 5 µl of 5 mg/ml Proteinase K was added to each sample before incubation at 60°C for 1 h. Finally, the LPS preparation was heated at 98°C for 10 min and stored at −20°C. LPS isolations were quantified by running the sample on an SDS-PAGE gel and comparing to five standards (10, 5, 1, 0.5, and 0.1 mg/ml) of commercially available *Pseudomonas aeruginosa* serotype 10 LPS (Sigma-Aldrich).

Bacterial cell fractions were visualized using SilverQuest kit (Invitrogen) or Western blotting ([@bib30]) using patient serum (1:200) and secondary antibody (1:5,000 alkaline phosphatase conjugated anti--human IgG, IgM or IgA; Sigma-Aldrich) before detection with nitro-blue tetrazolium and 5-bromo-4-chloro-3′-indolyphosphate as the substrate.

### Statistical methods.

All experiments were performed at least three times unless otherwise stated. Correlation was determined using Spearman's rank and Pearson product-moment correlation coefficients. Statistical significance between patient groups was determined by Student's *t* test. Error bars represent ± 1 standard error.

### Online supplemental material.

Fig. S1 gives an overview of all experiments performed with S1 serum and a summary of their results. Table S1 lists affinity of Protein A and Protein G for human immunoglobulins. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20132444/DC1>.
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